Acute phase protein biology and its representation in CRP/AGP ELISA kits

Acute phase proteins are plasma proteins whose concentrations shift in response to tissue injury, infection, or systemic inflammation, driven primarily by cytokine signaling (IL-6, IL-1, TNF-alpha) acting on hepatocytes. CRP is a positive acute phase reactant known for a comparatively rapid rise following an inflammatory trigger, followed by a relatively quick decline once the stimulus resolves, which makes it useful as a short-interval marker of active inflammation. AGP is also a positive acute phase reactant, but its kinetics are slower and more sustained, often remaining elevated over a longer period, which makes it more suited to tracking subacute or chronic inflammatory states rather than acute spikes.

These kinetic differences matter for ELISA kit selection and study design. A CRP panel is well suited to studies with frequent, closely spaced sampling timepoints intended to capture the onset and resolution of an inflammatory episode. An AGP panel is often paired with CRP in a two-marker design so that a research team can distinguish a brief inflammatory event (CRP up, AGP flat or mildly elevated) from a more prolonged process (both markers elevated, AGP remaining high after CRP normalizes). Because both proteins are produced predominantly in the liver, kits in this class are also used in hepatic function and metabolic stress research even outside of classic infection or injury models.

From a kit-design perspective, CRP and AGP assays are built as sandwich ELISAs using matched antibody pairs specific to the target species, since both proteins show meaningful sequence divergence across species — a human CRP antibody pair will not reliably quantify canine or feline CRP, and vice versa. This is why acute phase marker kits are organized by species within the catalog rather than offered as one universal format. Species-matched CRP and AGP kits are grouped together under acute phase inflammatory marker panels, with closely related oxidative stress markers available as a complementary research angle under the broader acute phase and inflammatory markers category.

Cross-species ELISA kit selection criteria based on sample type and biomarker target

Choosing the correct ELISA kit is a function of three variables: species, sample matrix, and the biological window the biomarker actually reflects. Getting any one of these wrong undermines data quality regardless of assay sensitivity.

Species specificity

Because antibody pairs are raised and validated against a defined target sequence, a kit labeled for one species should not be substituted for another even when the target protein shares a common name. Cross-reactivity, when it exists, is typically partial and unquantified unless explicitly stated, which makes unvalidated cross-species use a source of systematic error rather than simple noise.

Sample matrix compatibility

Most acute phase and inflammatory marker kits are validated for serum and plasma; some are also validated for urine or other matrices depending on the target's biology. Renal injury markers such as NGAL, for example, are frequently matrix-flexible because the analyte is informative in both plasma and urine, whereas classic acute phase proteins like CRP are almost always assessed in serum or plasma because that is where hepatic secretion products accumulate. Confirming matrix validation before sample collection avoids discovering, after the fact, that a planned urine cohort cannot be run on a serum-only kit.

Biomarker target and biological window

The same disease process can be approached through different biomarker classes depending on the research question. Acute inflammation favors CRP; chronic or subacute inflammation favors AGP; renal tubular injury favors NGAL or cystatin C; humoral immune status favors immunoglobulin class panels. A practical selection checklist includes: confirm species match, confirm sample matrix validation, confirm the biomarker's known kinetic profile matches the study's sampling schedule, and confirm the assay range covers the expected physiological or pathological concentration range for the cohort being studied.

Researchers working across both human and veterinary models will find it useful to review the full human ELISA kit category alongside the veterinary and animal ELISA kit category before finalizing a panel, since species-specific availability can shape which biomarkers are practical to pair in a single study.

General sandwich ELISA methodology and assay workflow principles

Nearly all of the kits discussed in this article, including CRP, AGP, NGAL, cystatin C, and the immunoglobulin class kits, use the sandwich ELISA format. Understanding this shared methodology clarifies why the selection criteria above apply broadly across biomarker classes.

1. Capture: A microplate is pre-coated with a capture antibody specific to the target analyte, immobilizing it to the well surface.
2. Sample and standard addition: Diluted samples and a dilution series of known-concentration standards are added, allowing the target analyte to bind the capture antibody.
3. Detection antibody binding: A second, detection antibody — typically conjugated to an enzyme such as horseradish peroxidase — binds a distinct epitope on the captured analyte, forming the antibody-antigen-antibody "sandwich."
4. Washing: Unbound material is removed between steps to control background signal.
5. Substrate reaction: A chromogenic substrate reacts with the conjugated enzyme, producing a color change proportional to analyte concentration.
6. Signal stop and read: A stop solution halts the reaction, and absorbance is read on a microplate reader, typically at 450 nm.
7. Quantification: Sample concentrations are interpolated from the standard curve generated from the known-concentration standards.

Two workflow principles are common sources of error regardless of which biomarker is being measured: standard curve placement and dilution planning. If sample concentrations fall outside the standard curve's linear range, results require re-testing at a different dilution rather than extrapolation. Second, because wash steps and incubation times are calibrated to the specific kit's chemistry, substituting protocols between kit lots or manufacturers — even for the same target — can introduce variability. For a fuller treatment of these workflow principles and how they generalize across the catalog, see the ELISA methodology applications resource.

Kidney injury biomarkers (NGAL, cystatin C) and their role in veterinary research panels

While CRP and AGP track systemic inflammation broadly, NGAL (neutrophil gelatinase-associated lipocalin) and cystatin C are organ-specific markers of renal injury that are frequently paired with acute phase panels in veterinary research examining systemic illness with renal involvement. NGAL is induced in renal tubular epithelial cells following injury and is detectable in both plasma and urine, giving it an advantage over traditional markers like creatinine, which typically only rise after substantial nephron loss has already occurred. Cystatin C is a low-molecular-weight protein filtered by the glomerulus and reabsorbed by the proximal tubule; its plasma level is less affected by factors like muscle mass than creatinine, making it a useful complementary marker of glomerular filtration in companion animal and research models.

In veterinary research, NGAL and cystatin C panels are often used alongside acute phase markers to differentiate systemic inflammatory stress from direct renal injury, or to confirm that an inflammatory insult has produced a measurable renal component. Because both markers are validated for urine in addition to serum or plasma in many kit formats, they also support non-invasive longitudinal sampling designs that would be impractical with serum-only markers. These kits are grouped under kidney injury marker panels within the broader renal and metabolic biomarker kit category, and a focused discussion of panel design is available in the companion article on kidney injury biomarkers in veterinary research.

Comparative overview of immunoglobulin class kits (IgG, IgA, IgM, IgE) across species

Immunoglobulin class quantification sits conceptually apart from acute phase and renal injury panels because it reflects adaptive humoral immune status rather than acute tissue response, but it is frequently requested alongside inflammation panels in studies examining infection, immunodeficiency, or allergic disease. Each immunoglobulin class reflects a distinct facet of immune function, and kit selection should match the class to the research question.

As with CRP and AGP, immunoglobulin ELISA kits are species-specific sandwich assays, and cross-species substitution is not appropriate given the structural divergence of immunoglobulin constant regions between species. Related literature on antibody deficiency presentations underscores why class-specific quantification, rather than total protein measurement, is necessary to characterize humoral immune status accurately. The full range of IgG subclass kits and combined IgA/IgM/IgE panels is organized under the immunoglobulin and antibody kit category, with a dedicated comparison available in immunoglobulin subclass ELISA kits explained.

Companion animal diagnostic panels for cats and dogs

Companion animal research frequently combines several of the biomarker classes discussed above into a single study design, since cats and dogs are common models for both spontaneous disease research and translational inflammation studies. A typical feline or canine diagnostic panel might pair a species-specific CRP or AGP kit to track systemic inflammation, a renal injury marker such as NGAL or cystatin C to monitor concurrent kidney involvement, and an immunoglobulin class kit to assess humoral immune competence, particularly in studies involving infectious disease models or immune-mediated conditions.

Because feline and canine acute phase responses differ in magnitude and kinetics from each other and from human responses, species-matched kits are essential rather than optional when building these panels — a canine CRP kit cannot be substituted for a feline one even though both measure a protein with the same name. Companion animal panels are consolidated under companion animal diagnostic kits, and a dedicated walkthrough of panel construction for cats and dogs is available in companion animal diagnostics: ELISA panels for cats and dogs.

Bringing the panel together

CRP and AGP remain the backbone of acute phase inflammation research because their distinct kinetics allow researchers to distinguish acute from subacute inflammatory processes within a single study design. Their diagnostic value increases substantially when paired with complementary markers: renal injury panels clarify whether inflammation has a measurable organ-specific component, and immunoglobulin class panels characterize the adaptive immune backdrop against which the inflammatory response is occurring. Selecting the right combination requires attention to species specificity, sample matrix validation, and the kinetic window each marker actually reflects — the same sandwich ELISA principles apply across all of these kit classes, which is why workflow consistency matters as much as marker selection. Readers building a multi-marker study should review the ELISA methodology and assay workflow resource for protocol-level guidance that applies across the full catalog, and consult the human and veterinary category pages directly when assembling a species-specific panel.

Related reading

• Antibody deficiency in myotonic dystrophy type 1: A differential diagnosis below the radar — background context on immunoglobulin deficiency presentation, not kit-specific validation.
• Development and characterization of a fully human recombinant MPO-ANCA monoclonal antibody as candidate quality control material — related immunoassay QC literature.
• Development of a colloidal gold immunochromatographic strip for rapid detection of Fasciola gigantica in buffaloes — related veterinary immunodiagnostic literature.
• Simplified ELISA for detecting antibodies to recombinant fusion proteins — general ELISA methodology literature.
• ELISA Kits — general reference literature on ELISA kit formats.
• HLA antibodies detected by ELISA HTLV-III antibody kits — historical ELISA antibody detection literature.

These references are provided as related background reading only and do not represent product-specific validation, performance claims, or protocol endorsements.